Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial.

Faria R, Bojke L, Epstein D, Corbacho B, Sculpher M; REFLUX trial group.

Br J Surg. 2013 Aug;100(9):1205-13. doi: 10.1002/bjs.9190. Epub 2013 Jun 17.

PMID:
23775366
2.

Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial).

Grant AM, Boachie C, Cotton SC, Faria R, Bojke L, Epstein DM, Ramsay CR, Corbacho B, Sculpher M, Krukowski ZH, Heading RC, Campbell MK; REFLUX trial group.

Health Technol Assess. 2013 Jun;17(22):1-167. doi: 10.3310/hta17220.

3.

Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX).

Grant AM, Cotton SC, Boachie C, Ramsay CR, Krukowski ZH, Heading RC, Campbell MK; REFLUX Trial Group.

BMJ. 2013 Apr 18;346:f1908. doi: 10.1136/bmj.f1908.

4.

The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.

Pells G, Mells GF, Carbone M, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, Neuberger JM, Day DB, Ducker SJ; UK-PBC Consortium, Sandford RN, Alexander GJ, Jones DE.

J Hepatol. 2013 Jul;59(1):67-73. doi: 10.1016/j.jhep.2013.02.019. Epub 2013 Mar 4.

PMID:
23466308
5.

Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.

Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, Neuberger JM, Day DB, Ducker SJ; UK PBC Consortium, Sandford RN, Alexander GJ, Jones DE.

Gastroenterology. 2013 Mar;144(3):560-569.e7; quiz e13-4. doi: 10.1053/j.gastro.2012.12.005. Epub 2012 Dec 12.

PMID:
23246637
6.

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.

Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, Ducker SJ, Muriithi AW, Wheater EF, Hammond CJ, Dawwas MF; UK PBC Consortium; Wellcome Trust Case Control Consortium 3, Jones DE, Peltonen L, Alexander GJ, Sandford RN, Anderson CA.

Nat Genet. 2011 Mar 13;43(4):329-32. doi: 10.1038/ng.789. Erratum in: Nat Genet. 2011 Nov;43(11):1164. Richardson,Paul [added]; Nasr, Ikram [added]; Aspinall,Richard [added].

7.

Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study.

Epstein D, Bojke L, Sculpher MJ; REFLUX trial group.

BMJ. 2009 Jul 14;339:b2576. doi: 10.1136/bmj.b2576.

8.

Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial.

Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, Thursz MR, Campbell MK; REFLUX Trial Group.

BMJ. 2008 Dec 15;337:a2664. doi: 10.1136/bmj.a2664.

9.

The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.

Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, Thursz M, Russell I, Campbell M; REFLUX Trial Group.

Health Technol Assess. 2008 Sep;12(31):1-181, iii-iv.

10.

The mucosal anaerobic gram-negative bacteria of the human colon.

Poxton IR, Brown R, Sawyerr A, Ferguson A.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S111-3. No abstract available.

11.

Mucosa-associated bacterial flora of the human colon.

Poxton IR, Brown R, Sawyerr A, Ferguson A.

J Med Microbiol. 1997 Jan;46(1):85-91.

PMID:
9003751
12.

Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects.

Fraser AG, Sawyerr AM, Hudson M, Smith MS, Pounder RE.

Aliment Pharmacol Ther. 1996 Aug;10(4):523-7.

PMID:
8853755
13.

Satisfactory outcome of percutaneous endoscopic gastrostomy in two patients with cirrhosis and portal hypertension.

Sawyerr AM, Ghosh S, Eastwood MA.

Am J Gastroenterol. 1995 May;90(5):826-8. No abstract available.

PMID:
7733098
14.

Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases.

Sawyerr AM, Smith MS, Hall A, Hudson M, Hay CR, Wakefield AJ, Brook MG, Tomura H, Pounder RE.

Dig Dis Sci. 1995 Apr;40(4):793-9.

PMID:
7720471
15.

Serum immunoglobulin G reactive with endothelial cells in inflammatory bowel disease.

Sawyerr AM, Pottinger BE, Savage CO, Bradley NJ, Hudson M, Wakefield AJ, Pearson JD, Pounder RE.

Dig Dis Sci. 1994 Sep;39(9):1909-17.

PMID:
8082497
16.

Ulcerative colitis and Crohn's disease: similarities and distinctions.

Sawyerr AM, Ferguson A.

J R Coll Physicians Lond. 1994 May-Jun;28(3):197-9. No abstract available.

PMID:
7932315
17.

Effects of ranitidine 150 mg four times a day on 24-hour intragastric acidity and 24-hour plasma gastrin concentration.

Fraser AG, Sawyerr AM, Hudson M, Smith M, Pounder RE.

Dig Dis Sci. 1994 Jan;39(1):91-6.

PMID:
8281874
18.

Failure of percutaneous endoscopic gastrostomy insertion.

Ghosh S, Sawyerr A, Eastwood MA.

Am J Gastroenterol. 1993 Jun;88(6):968. No abstract available.

PMID:
8503402
19.

Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity.

Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE.

Aliment Pharmacol Ther. 1993 Jun;7(3):317-21. Erratum in: Aliment Pharmacol Ther 1993 Oct;7(5):587.

PMID:
8117350
20.

Early mucosal changes in Crohn's disease.

Sankey EA, Dhillon AP, Anthony A, Wakefield AJ, Sim R, More L, Hudson M, Sawyerr AM, Pounder RE.

Gut. 1993 Mar;34(3):375-81.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk